PIgR: Frenemy of inflammation, EMT, and HCC progression

Journal of the National Cancer Institute

Volumn 103, Issue 22, 2011, Pages 1644-1645

  Sphyris, Nathalie ^a   Mani, Sendurai A ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Metastasis Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; SECRETORY COMPONENT; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER RECURRENCE; CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; HEPATITIS B; HUMAN; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; LIVER CELL CARCINOMA; LUNG METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCYTOSIS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MESENCHYMAL STROMAL CELLS; RECEPTORS, POLYMERIC IMMUNOGLOBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 81855183777     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr421     Document Type: Article

References (25)

1. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22(33):5093-5107. (Pubitemid 37059591)
2. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25(27):3866-3884. (Pubitemid 43980482)
3. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol. 2011. doi:10.1016/j.jhep.2011.07.007.
4. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007;46(2):590-597. (Pubitemid 47344795)
5. Choi SS, Diehl AM. Epithelial-to-mesenchymal transitions in the liver. Hepatology. 2009;50(6):2007-2013.
6. Jou J, Diehl AM. Epithelial-mesenchymal transitions and hepatocarcinogenesis. J Clin Invest. 2010;120(4):1031-1034.
7. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-1428.
8. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741-4751.
9. Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1(6-7):303-314.
10. van ZF, Zulehner G, Petz M, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 2009;5(8):1169-1179.
11. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15(5):416-428.
12. Ai J, Tang Q, Wu Y, et al. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J Natl Cancer Inst. 2011;103(22):1696-1712.
13. Rossel M, Seilles E, Voigt JJ, Vuitton D, Legait N, Revillard JP. Polymeric Ig receptor expression in hepatocellular carcinoma. Eur J Cancer. 1992;28A(6-7):1120-1124.
14. Asano M, Komiyama K. Polymeric immunoglobulin receptor. J Oral Sci. 2011;53(2):147-156.
15. Mantel PY, Schmidt-Weber CB. Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol Biol. 2011;677(2):303-338.
16. Meulmeester E, Ten DP. The dynamic roles of TGF-beta in cancer. J Pathol. 2011;223(2):205-218.
17. Battaglia S, Benzoubir N, Nobilet S, et al. Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One. 2009;4(2):e4355.
18. Mu Y, Gudey SK, Landstrom M. Non-Smad signaling pathways. Cell Tissue Res. 2011. doi:10.1007/s00441-011-1201-y.
19. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell. 1998;95(6):779-791. (Pubitemid 29014458)
20. Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, Wu J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol. 2011;55(4):838-845.
21. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-715. (Pubitemid 351636299)
22. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008;3(8):e2888.
23. Arzumanyan A, Friedman T, Ng IO, Clayton MM, Lian Z, Feitelson MA. Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res. 2011;71(10):3701-3708.
24. Kim HM, Haraguchi N, Ishii H, et al. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. Ann Surg Oncol. 2011. doi:10.1245/s10434-011-2040-5.
25. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006;25(27):3818-3822. (Pubitemid 43980477)